A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis

ConclusionThe absolute SI rates were low. However across the JAK inhibitors, the incidence of HZ is higher than expected for the population (3.23 per 100 patient-years). While the risk was numerically greatest with baricitinib, indirect comparisons between the drugs did not demonstrate any significant difference in risk.Systematic review registration numberProspero 2017 CRD4201707879.
Source: Rheumatology - Category: Rheumatology Source Type: research